32results about How to "Lower viral load" patented technology

The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.

The present invention provides methods for lowering a viral load of a virus resistant to an antiviral drug by inducing cytotoxic T lymphocytes (CTL) to recognize a predetermined mutated epitope within a viral protein of the drug-resistant virus. CTLs are induced by immunizing a host with a peptide comprising the predetermined mutation. The immunostimulating peptide may be further improved by epitope-enhancement for inducing specific CTLs. The antiviral protection against drug-resistant virus shown by compositions of the present invention and mediated by human HLA-restricted CTL has not been previously achieved.

The invention discloses compounds having virus resistance and a composition thereof. The composition comprises one or more of the 13 compounds comprising 6'-O-caffeoyl deacetyl asperulosidic acid methyl ester. The compounds having virus resistance and the composition thereof can be extracted from plants and can also be prepared by synthesis. The composition comprising the compounds having virus resistance can prevent and treat viral infection-caused diseases such as influenza, myocarditis, conjunctivitis, viral pneumonia, encephalitis, leukemia, hepatitis B, hepatitis C, AIDS, genitourinary system infection, EB virus infection, human papillomavirus infection and cytomegalovirus infection. The composition can be prepared into an oral preparation, an injection, a spray, a subcutaneous injection and an anus suppository.

The invention discloses a recombinant novel coronavirus (SARS-CoV-2) vaccine composition. The vaccine composition comprises a recombinant spike protein with an amino acid sequence shown in SEQ ID NO:1. The vaccine composition further comprises a pharmaceutically acceptable carrier, such as an aluminum adjuvant in combination with a CpG ODN adjuvant. The vaccine composition shows excellent immunogenicity in mice, and can induce an organism to generate high-titer antibody response biased to Th1 and high-level cellular immune response. Animal model experiments show that the vaccine composition can induce high-titer neutralizing antibodies and significantly reduce the viral load inside lung and turbinate tissues.

The invention discloses a drug delivery system for external use containing the effective composition of bullatacin locality drug; the effective composition containing the bullatacin locality drug is dissolved in a mixed liquid of absolute alcohol and propylene glycol and fully stirred and mixed, and then prepared into the drug delivery system for external use; the drug delivery system comprises a patch, an aerosol or a film agent. Adoptions of the natural substance bullatacin extracted from cherimoya and an external using manner of the invention overcomes the shortcoming that the antitumor drugs and anti-AIDS drug have to be orally used or intravenously medicated, and the drug delivery system can ensure the drug to be absorbed through the skin, thus slowly releasing the drug and reducing the delivery dosage of the drug and the economic cost for the treatment.

The invention discloses a porcine epidemic diarrhea virus vaccine strain and a preparation method thereof. The vaccine strain is obtained by continuously transmitting FJzz1 to 200 generations in Vero cells. Low-generation FJzz1-F20 and high-generation FJzz1-F200 strains are selected to perform pathogenicity evaluation on piglets, and the result shows that the clinical manifestation of the piglets in a high-generation FJzz1-F200 infection group is obviously lighter than that of the piglets in an FJzz1-F20 infection group, and the diseased pigs do not die. Compared with the FJzz1-F20 infection group, the excrement toxin expelling amount of the piglets in the FJzz1-F200 infection group and the viral load in intestinal tissues are remarkably reduced, and the intestinal tissues are not subjected to obvious histopathological changes. Meanwhile, detection finds that the FJzz1-F200 infection group can induce high-level I-type and III-type interferon generation in the intestinal tissues. The research result shows that the FJzz1-F200 is weak in pathogenicity and has the potential of serving as a PEDV candidate attenuated vaccine strain.

The embodiment of the invention provides application of a lung-ventilating and toxin-vanquishing prescription or an extract of the lung-ventilating and toxin-vanquishing prescription to preparation of a medicine for preventing and/or treating pneumonia caused by influenza A virus H1N1, wherein the lung-ventilating and toxin-vanquishing prescription comprises the following components in parts by weight: 5-7 parts of raw ephedra, 28-32 parts of gypsum, 28-32 parts of raw coix seeds, 13-17 parts of bitter apricot kernels, 8-12 parts of rhizoma atractylodis lanceae, 13-17 parts of pogostemon cablin, 10-14 parts of artemisia apiacea, 28-32 parts of dried rhizoma phragmitis, 13-17 parts of pummelo peel, 18-22 parts of polygonum cuspidatum, 28-32 parts of verbena, 13-17 parts of semen lepidii and 8-12 parts of raw liquorice. The lung-ventilating and toxin-vanquishing prescription and the extract thereof provided by the invention can reduce the virus load, reduce the expression of proinflammatory factors, promote the expression of anti-inflammatory factors and improve pulmonary symptoms, so that the lung-ventilating and toxin-vanquishing prescription and the extract thereof can be used for preventing and/or treating pneumonia caused by the influenza A virus H1N1.

The invention discloses an anti-HPV infection medicine, which comprises the following raw material medicines in parts by weight: 10-20 parts of radix sophorae flavescentis, 10-20 parts of phellodendron amurense, 6-12 parts by weight of cortex dictamn, 4-8 parts by weight of safflower; 2-4 parts by weight of fructus cnidii; 3-5 parts by weight of Radix Astragali; 2-4 parts by weight of aloe; and 0.5-3 parts by weight of bunge corydalis herb. The invention discloses the anti-HPV infection medicine, the clinical symptoms and signs of patients can be obviously improved; the virus load capacity ofa virus infected person is effectively reduced; the medicine for treating the heart disease is prepared from the following raw materials: radix sophorae flavescentis, phellodendron amurense, cortex dictamni, safflower, fructus cnidii, Radix Astragali, aloe, bunge corydalis herb, borneol, perilla stems, eupatorium, campsis grandiflora, ground beetle, cortex magnoliae officinalis, rhinacanthus nasutus and rhizoma alismatis. Through reasonable compatibility of all the raw materials, the special performance and effects of all the raw materials are fully exerted, meanwhile, the complementary effectof all the raw materials is considered, the medicine effects supplement each other, the condyloma acuminatum treatment effect is remarkable, and no toxic or side effect exists.

Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

The present invention provides a new vector for gene therapy said vector being therapeutically very efficient, viral particles comprising said vector, compositions comprising said viral particle, uses thereof, methods for the preparation of the vector), and therapies using said vector.

The invention belongs to the technical field of medicines, and discloses application of a compound in preparation of an antiviral drug. The compound N-[(2-methoxyphenyl) methyl]-2-[4-(4-methoxyphenyl)-2-oxybenzopyran-7-yl] oxyacetamide has a new application in medicine, and the application refers to a new application in virus resistance, especially in the aspect of pneumonia caused by coronavirus. The invention proves that the compound has the effects of remarkably inhibiting the lung index and reducing the lung virus load, and the effect of the compound is superior to that of a positive drug chloroquine phosphate and Lanhuaqing pestilence. The action mechanism of the compound for resisting viral pneumonia is related to the aspects of regulating expression of inflammatory factors, regulating differentiation of immune cells, inhibiting generation of free radicals and the like. The N-[(2-methoxyphenyl) methyl]-2-[4-(4-methoxyphenyl)-2-oxybenzopyran-7-yl] oxyacetamide can be used as a safe and effective novel clinical candidate drug for resisting viruses.

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

The invention discloses novel application of azidothymidine in treating leukaemia. Pharmacodynamic experiments show that the azidothymidine has functions of inhibiting the growth of human leukaemia cells Jukat and murine leukemia cells L615, can inhibit the infiltrations of mouse peripheral blood, marrow and liver and spleen organizations, remarkably prolong the life cycle of a leukaemia mouse, and effectively reduce the leucovirus load of a Friend mouse spleen, and has significant effect on treating acute erythroleukemia induced by Friend mouse leucovirus.

The invention relates to an anti-virus Chinese herbal medicine product, wherein Chinese medicinal herbs or their extracts are employed as the raw material, which can be used for antiviral, in particular the treatment of HIV/AIDS. The invention also relates to the method for treating viral infection of homothermal animal by employing the medicinal product. The invention also relates to the process for preparing the product and the compostion.

Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.

The invention provides an HSV-2 DNA vaccine used by mucous membranes. The HSV-2 DNA vaccine comprises pgD, pCCL28 and immune mediators, wherein the pgD is a pcDNA3.1(+) plasmid including a nucleotide sequence of HSV-2 gD envelope glycoprotein; the pCCL28 is a pcDNA3.1(+) plasmid including a nucleotide sequence of CCL28; and the vaccine is immunized or used by the mucous membranes. The invention also provides a preparation method of the vaccine. In addition, the invention provides an application of the vaccine in preventing and treating herpes simplex virus infection and treating diseases related to the herpes simplex virus. The HSV-2 DNA vaccine provided by the invention has an ideal immune protection effect and HSV-2 control and disease treatment effects, is convenient in promotion and use, easy in quality control and large-scale production, storage and transportation, low in cost and simple in operation, and has good market application prospects.

The invention relates to a compound for treating and/or preventing hepatitis B virus infection as well as a preparation method and application thereof. Specifically, the compound disclosed by the invention has a structure shown as a formula I, and the definitions of all groups and substituents are as described in the specification. The compound has higher activity, better in-vivo drug effect, better safety, better pharmacokinetic property and better druggability.